Aaron E Alt, the Chief Financial Officer of $CAH, sold 2,328 shares of the company on 02-18-2026 for an estimated $524,964. We received data on the trade from a recent SEC filing. This was a sale of approximately 8.1% of their shares of this class of stock. Following this trade, they now own 26,408 shares of this class of $CAH stock.
$CAH Insider Trading Activity
$CAH insiders have traded $CAH stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $CAH stock by insiders over the last 6 months:
- JASON M. HOLLAR (Chief Executive Officer) has made 0 purchases and 2 sales selling 35,901 shares for an estimated $5,386,566.
- DEBORAH WEITZMAN (CEO, PSS Segment) sold 21,367 shares for an estimated $3,216,374
- AARON E ALT (Chief Financial Officer) sold 2,328 shares for an estimated $524,964
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$CAH Hedge Fund Activity
We have seen 662 institutional investors add shares of $CAH stock to their portfolio, and 629 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 7,746,239 shares (-77.0%) from their portfolio in Q4 2025, for an estimated $1,591,852,114
- WCM INVESTMENT MANAGEMENT, LLC added 4,032,682 shares (+inf%) to their portfolio in Q4 2025, for an estimated $828,716,151
- BLACKROCK, INC. removed 2,823,035 shares (-9.0%) from their portfolio in Q4 2025, for an estimated $580,133,692
- MILLENNIUM MANAGEMENT LLC removed 1,580,019 shares (-79.6%) from their portfolio in Q4 2025, for an estimated $324,693,904
- HOLOCENE ADVISORS, LP removed 936,677 shares (-48.6%) from their portfolio in Q4 2025, for an estimated $192,487,123
- CITADEL ADVISORS LLC added 934,750 shares (+99.2%) to their portfolio in Q4 2025, for an estimated $192,091,125
- MARSHALL WACE, LLP added 884,648 shares (+1328.1%) to their portfolio in Q4 2025, for an estimated $181,795,164
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$CAH Revenue
$CAH had revenues of $65.6B in Q2 2026. This is an increase of 18.75% from the same period in the prior year.
You can track CAH financials on Quiver Quantitative's CAH stock page.
$CAH Congressional Stock Trading
Members of Congress have traded $CAH stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $CAH stock by members of Congress over the last 6 months:
- REPRESENTATIVE MARJORIE TAYLOR GREENE purchased up to $15,000 on 10/24.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$CAH Analyst Ratings
Wall Street analysts have issued reports on $CAH in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 01/29/2026
- Mizuho issued a "Outperform" rating on 11/04/2025
- TD Cowen issued a "Buy" rating on 11/03/2025
- UBS issued a "Buy" rating on 10/31/2025
To track analyst ratings and price targets for $CAH, check out Quiver Quantitative's $CAH forecast page.
$CAH Price Targets
Multiple analysts have issued price targets for $CAH recently. We have seen 9 analysts offer price targets for $CAH in the last 6 months, with a median target of $243.0.
Here are some recent targets:
- Lisa Gill from JP Morgan set a target price of $243.0 on 02/10/2026
- Stephen Baxter from Wells Fargo set a target price of $256.0 on 02/10/2026
- Steven Valiquette from Mizuho set a target price of $235.0 on 02/06/2026
- Erin Wright from Morgan Stanley set a target price of $245.0 on 01/29/2026
- Daniel Grosslight from Citigroup set a target price of $244.0 on 01/09/2026
- Glen Santangelo from Barclays set a target price of $243.0 on 12/09/2025
- Charles Rhyee from TD Cowen set a target price of $225.0 on 11/03/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
